Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa

Molecular Cancer Therapeutics

Volumn 7, Issue 7, 2008, Pages 2192-2202

  Meng, Yang ^a   Tang, Wenhua ^a   Dai, Yao ^a   Wu, Xiaoqing ^b   Liu, Meilan ^a   Ji, Qing ^a   Ji, Min ^b   Pienta, Kenneth ^a   Lawrence, Theodore ^a   Xu, Liang ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^b SOUTHEAST UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; GOSSYPOL; INTERLEUKIN 3; PROTEIN BAD; PROTEIN BAX; PROTEIN BCL XL; PROTEIN NOXA; PUMA PROTEIN; SMALL INTERFERING RNA; APOPTOSIS REGULATORY PROTEIN; BBC3 PROTEIN, HUMAN; ONCOPROTEIN; PMAIP1 PROTEIN, HUMAN; PROTEIN BAK; PROTEIN BCL 2; PROTEIN BCL X; TAXOID;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL DEATH; CELL GROWTH; CHEMOSENSITIZATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMAN; HUMAN CELL; MALE; MITOCHONDRION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANIMAL; CELL PROLIFERATION; DIMERIZATION; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; METABOLISM; NUDE MOUSE; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; CELL LINE, TUMOR; CELL PROLIFERATION; DIMERIZATION; DOSE-RESPONSE RELATIONSHIP, DRUG; GOSSYPOL; HUMANS; INTERLEUKIN-3; MALE; MICE; MICE, NUDE; MITOCHONDRIA; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, SMALL INTERFERING; TAXOIDS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 51049106854     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0333     Document Type: Article

References (43)

1. Assikis V, Simons JW. Novel therapeutic strategies for androgen-independent prostate cancer: an update. Semin Oncol 2004;31:26-32.
2. Oh WK, Kantoff PW. Management of hormone refractory prostate cancer: current standards and future prospects. J Urol 1998;160:1220-9.
3. Rago R. Management of hormone-sensitive and hormone-refractory metastatic prostate cancer. Cancer Control 1998;5:513-21.
4. Reed JC. Bcl-2 family proteins: strategies for overcoming chemoresistance in cancer. Adv Pharmacol 1997;41:501-32.
5. Reed JC, Jurgensmeier JM, Matsuyama S. Bcl-2 family proteins and mitochondria. Biochim Biophys Acta 1998;1366:127-37.
6. Korsmeyer SJ. Bcl-2 gene family and the regulation of programmed cell death. Cancer Res 1999;59:1693-700s.
7. Makin G, Dive C. Apoptosis and cancer chemotherapy. Trends Cell Biol 2001;11:S22-6.
8. + cells. Br J Haematol 2002;118:521-34.
9. Furuya Y, Krajewski S, Epstein JI, Reed JC, Isaacs JT. Expression of Bcl-2 and the progression of human and rodent prostatic cancers. Clin Cancer Res 1996;2:389-98.
10. Krajewska M, Krajewski S, Epstein JI, et al. Immunohistochemical analysis of Bcl-2, Bax, Bcl-x, and Mcl-1 expression in prostate cancers. Am J Pathol 1996;148:1567-76.
11. Beale PJ, Rogers P, Boxall F, Sharp SY, Kelland LR. Bcl-2 family protein expression and platinum drug resistance in ovarian carcinoma. Br J Cancer 2000;82:436-40.
12. Ferlini C, Raspaglio G, Mozzetti S, et al. Bcl-2 down-regulation is a novel mechanism of paclitaxel resistance. Mol Pharmacol 2003;64:51-8.
13. Grad JM, Zeng XR, Boise LH. Regulation of Bcl-xl: a little bit of this and a little bit of Stat. Curr Opin Oncol 2000;12:543-9.
14. Lebedeva I, Rando R, Ojwang J, Cossum P, Stein CA. Bcl-xl in prostate cancer cells: effects of overexpression and down-regulation on chemosensitivity. Cancer Res 2000;60:6052-60.
15. Gleave M, Nelson C, Chi K. Antisense targets to enhance hormone and cytotoxic therapies in advanced prostate cancer. Curr Drug Targets 2003;4:209-21.
16. Kim H, Rafiuddin-Shah M, Tu HC, et al. Hierarchical regulation of mitochondrion-dependent apoptosis by Bcl-2 subfamilies. Nat Cell Biol 2006;8:1348-58.
17. Willis SN, Chen L, Dewson G, et al. Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xl, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev 2005;19:1294-305.
18. Adams KW, Cooper GM. Rapid turnover of Mcl-1 couples translation to cell survival and apoptosis. J Biol Chem 2007;282:6192-200.
19. Kitada S, Leone M, Sareth S, Zhai D, Reed JC, Pellecchia M. Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins. J Med Chem 2003;46:4259-64.
20. Xu L, Yang D, Wang S, et al. (-)-Gossypol enhances response to radiation therapy and results in tumor regression of human prostate cancer. Mol Cancer Ther 2005;4:197-205.
21. Simonian PL, Grillot DA, Nunez G. Bcl-2 and Bcl-xl can differentially block chemotherapy-induced cell death. Blood 1997;90:1208-16.
22. Biggiogera M, Bottone MG, Pellicciari C. Nuclear ribonucleoprotein- containing structures undergo severe rearrangement during spontaneous thymocyte apoptosis. A morphological study by electron microscopy. Histochem Cell Biol 1997;107:331-6.
23. Degterev A, Lugovskoy A, Cardone M, et al. Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xl [comment]. Nat Cell Biol 2001;3:173-82.
24. Perez-Galan P, Roue G, Villamor N, Montserrat E, Campo E, Colomer D. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of Ros and Noxa activation independent of p53 status. Blood 2006;107:257-64.
25. Castedo M, Coquelle A, Vivet S, et al. Apoptosis regulation in tetraploid cancer cells. EMBO J 2006;25:2584-95.
26. Susin SA, Lorenzo HK, Zamzami N, et al. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 1999;397:441-6.
27. Donovan M, Cotter TG. Control of mitochondrial integrity by Bcl-2 family members and caspase-independent cell death. Biochim Biophys Acta 2004;1644:133-47.
28. Smaili SS, Hsu YT, Sanders KM, Russell JT, Youle RJ. Bax translocation to mitochondria subsequent to a rapid loss of mitochondrial membrane potential. Cell Death Differ 2001;8:909-20.
29. Mohammad RM, Wang S, Aboukameel A, et al. Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-x(l) [(-)-gossypol] against diffuse large cell lymphoma. Mol Cancer Ther 2005;4:13-21.
30. Podar K, Gouill SL, Zhang J, et al. A pivotal role for Mcl-1 in bortezomib-induced apoptosis. Oncogene 2008;27:721-31.
31. Gomez-Bougie P, Oliver L, Le Gouill S, Bataille R, Amiot M. Melphalan-induced apoptosis in multiple myeloma cells is associated with a cleavage of Mcl-1 and Bim and a decrease in the Mcl-1/Bim complex. Oncogene 2005;24:8076-9.
32. Nunez G, London L, Hockenbery D, Alexander M, McKearn JP, Korsmeyer SJ. Deregulated bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines. J Immunol 1990;144:3602-10.
33. Boise LH, Gonzalez-Garcia M, Postema CE, et al. Bcl-x, a Bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993;74:597-608.
34. Corbett TH. Transplantable syngeneic rodent tumors. Totowa: Humana Press; 2002.
35. Zhang M, Liu H, Guo R, et al. Molecular mechanism of gossypol-induced cell growth inhibition and cell death of HT-29 human colon carcinoma cells. Biochem Pharmacol 2003;66:93-103.
36. Oliver CL, Miranda MB, Shangary S, Land S, Wang S, Johnson DE. (-)-Gossypol acts directly on the mitochondria to overcome Bcl-2- and Bcl-x(l)-mediated apoptosis resistance. Mol Cancer Ther 2005;4:23-31.
37. Oliver CL, Bauer JA, Wolter KG, et al. In vitro effects of the BH3 mimetic, (-)-gossypol, on head and neck squamous cell carcinoma cells. Clin Cancer Res 2004;10:7757-63.
38. Adams JM, Cory S. The bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007;26:1324-37.
39. Villunger A, Michalak EM, Coultas L, et al. p53- and drug-induced apoptotic responses mediated by BH3-only proteins Puma and Noxa. Science 2003;302:1036-8.
40. Lee EF, Czabotar PE, van Delft MF, et al. A novel BH3 ligand that selectively targets mcl-1 reveals that apoptosis can proceed without Mcl-1 degradation. J Cell Biol 2008;180:341-55.
41. Han J, Goldstein LA, Hou W, Rabinowich H. Functional linkage between noxa and bim in mitochondrial apoptotic events. J Biol Chem 2007;282:16223-31.
42. Denisov AY, Sprules T, Fraser J, Kozlov G, Gehring K. Heat-induced dimerization of bcl-xl through a-helix swapping. Biochemistry 2007;46:734-40.
43. Wolter KG, Verhaegen M, Fernandez Y, et al. Therapeutic window for melanoma treatment provided by selective effects of the proteasome on Bcl-2 proteins. Cell Death Differ 2007;14:1605-16.